Halozyme Therapeutics Investor Presentation — May 2021

Document content

Corporate Presentation

May 2021Forward -Looking Statements

2Note: This presentation contains product names, trademarks and registered trademarks are property of their respective ownersIn addition to historical information, the statements set forth in this presentation include forward -looking statements includin g, without limitation, statements

concerning the Company’s expected future financial performance (including the Company's financial outlook for 2021) and expec tations for profitability,

revenue (including expectations for future milestones and royalty growth), operating income, expenses and earnings -per-share and the Company’s plans to

continue its share repurchase program and to potentially expand its platform through acquisitions. Forward -looking statements r egarding the Company’s

ENHANZE® drug delivery technology may include the possible activity, benefits and attributes of ENHANZE®, the possible method ofaction of ENHANZE®, its

potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery of injectable medications

through subcutaneous delivery. Forward -looking statements regarding the Company's ENHANZE® business may include potential growth driven by our

partners' development and commercialization efforts (including anticipated new clinical trial starts and ENHANZE ® product laun ches), projections for future

sales revenue of our collaborators’ products, potential new ENHANZE® collaborations and collaborative targets and potential a pprovals of new ENHANZE®

products. These forward -looking statements are typically, but not always, identified through use of the words "believe," "enable ," "may," "will," "could," "intends,"

"estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of si milar meaning and involve risk and

uncertainties that could cause actual results to differ materially from those in the forward -looking statements. Actual results could differ materially from the

expectations contained in these forward -looking statements as a result of several factors, including unexpected levels of revenu es (including royalty and

milestone revenue received from our collaboration partners), expenditures and costs, unexpected delays in the execution of th e Company's share

repurchase program or planned platform expansion, unexpected results or delays in the growth of the Company’s ENHANZE® busine ss,or in the development,

regulatory review or commercialization of ENHANZE® products, including any potential delays caused by the current COVID -19 globa l pandemic, regulatory

approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences